人物經歷
教育經歷
1990年7月本科畢業於四川大學化學系，1998年獲中科院上海有機化學研究所博士。
![田紅旗[南開大學藥學院教授]](/img/e/87b/wZwpmL3YDN5ETM3gjN0kTO0UTMyITNykTO0EDMwAjMwUzL4YzL0czLt92YucmbvRWdo5Cd0FmL0E2LvoDc0RHa.jpg)
田紅旗[南開大學藥學院教授]工作經歷
2010年6月至今，南開大學藥學院教授，博士生導師；
2001年6月至今，阿瑞製藥公司， 高級研究科學家（Senior Research Scientist）；1998年9月至2001年5月，科羅拉多大學化學系博士後；
1990年7月至1993年8月,原化學工業部感光化學研究院助理工程師。
研究方向
通過結構-活性關係（SAR）的研究對先導化合物進行最佳最佳化來開發新藥；對受體蛋白激酶領域的靶標受體有一定程度的了解，並據此提出治療癌症的新藥開發的項目；具有開發新有機反應方法學研究的特長；具有對有機化合物進行工業化工藝研究的特長；熟悉通過各種分析儀器（如核磁共振、液-質聯用儀、液相色譜、氣相色譜、紅外和質譜儀等）對有機化合物進行結構確定，及其他各種所需要的特徵化。
主要貢獻
1. Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety. T. Richardson; S. Frank; M. Wang; C. Clarke; S. Jones; B. Ying; D. Kohlman; O. Wallace; T. Shepherd; R. Dally; A. Palkowitz; A. Geiser; H. Bryant; J. Henck; I. Cohen; D. Rudmann; D. McCann; D. Coutant; S. Oldham; C. Hummel; K. Fong; R. Hinklin; G. Lewis; H. Tian; J. Dodge. Bioorganic & Medicinal Chemistry Letters, 2007, 17(13), 3544-3549.
2. A Selective Estrogen Receptor Modulator Designed for the Treatment of Uterine Leiomyoma with Unique Tissue Specificity for Uterus and Ovaries in Rats. C. Hummel; A. Geiser; H. Bryant; I. Cohen; R. Dally; K. Fong; S. Frank; R. Hinklin; S. Jones; G. Lewis; D. McCann; D. Rudmann; T. Shepherd; H. Tian; O. Wallace; M. Wang; Y. Wang; J. Dodge. Journal of Medicinal Chemistry, 2005, 48(22), 6772-6775.
3. Asymmetric Strecker Reaction of g-Keto Acids. Facile Entry to a-Substituted and a,g-Disubstituted Glutamic Acids. G. Tang, H. Tian, D. Ma*, Tetrahedron, 2004, 60(46), 10547-10552.
4. Asymmetric Synthesis of (S)-1-Aminoindan-1,5-dicarboxylic Acid and Related Analogues via Intramolecular Acylation of Enantiopure α,α-Disubtituted Amino Acids. D. Ma*, D. Ke, H. Tian, B. Wang, D. Cheng, Tetrahedron: Asymmetry, 2002, 13(9), 961-969.
5. Designing New Chiral Ketone Catalysts. Enantioselective Epoxidation of cis- and Terminal Olefins, H. Tian, X. She, H. Yu, L. Shu, Y. Shi*, J. Org. Chem., 2002, 67(8), 2435-2446.
6. Enantioselective Epoxidation of Terminal Olefins by Chiral Dioxriane, H. Tian, X. She, J. Xu, Y. Shi*, Org. Lett., 2001, 3(12), 1929-1931.
7. Electronic Probing of Ketone Catalysts for Asymmetric Epoxidation. Search for More Robust Catalyst, H. Tian, X. She, Y. Shi*, Org. Lett., 2001, 3(5), 715-718.
8. Highly Enantioselective Epoxidation of cis-Olefins by Chiral Dioxirane, H. Tian, X. She, L. Shu, H. Yu, Y. Shi*, J. Am. Chem. Soc., 2000, 122, 11551-11552.
9. Oxidation of Benzylic Methylene Compounds to Ketones with m- Chloroperoxybenzoic Acid and Oxygen, D. Ma*, C. Xia, H. Tian, Tetrahedron Lett. 1999, 40(50), 8915-8917.
10. Enantioselective Syntheses of a-Substituted Glutamic Acids and a, g- Disubstituted Glutamic Acids by an Asymmetric Strecker Reaction, D. Ma*, G. Tang, H. Tian, G. Zou, Tetrahedron Lett. 1999, 40(31), 5753-5756.
11. Asymmetric Strecker-Type Reaction of a-Aryl Ketones. Synthesis of s-aM4CPG, s-MPPG, s-AIDA, and s-APICA, the Antagonists of Metabotropic Glutamate Receptors, D. Ma*, H. Tian, G. Zou, J. Org. Chem., 1999, 64(1), 120-125.
12. Stereoselective Synthesis of s-MPPG, s-MTPG, and s-(+)-aM4CPG from R-4-Hydroxyphenylglycine, D. Ma*, H. Tian, J. Chem. Soc. Perkin. Transactions I, 1997, 23, 3493-3496.
13. Synthesis and Biological Activity of Cyclic Analogues of MPPG and MCPG as Metabotropic Receptor Antagonists, D. Ma*, H. Tian, H. Sun, A. P. Kozikowski, S. Pshenichkin, J. T. Wroblewsk, Biorg. & Med. Chem. Lett., 1997, 7(9), 1195-1198.
14. Asymmetric Synthesis of (+)-4CPMG, a Selective Antagonist of Metabotropic Glutamate Receptors, D. Ma*, H. Tian. Tetrahedron: Asymmetry, 1996, 7(6), 1567-1570.
發表的專利
1. Preparation of pyrrolidinone and piperidinone derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1. T. Aicher; M. Chicarelli; C. Gauthier; R. Hinklin; H. Tian; O. Wallace.
2. Preparation of pyrrolidones and piperidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1. T. Aicher; M. Chicarelli; C. Gauthier; R. Hinklin; H. Tian; O. Wallace; A. Krasutsky; J. Allen.
3. Preparation of cycloalkyl lactam derivatives, particularly N-substituted pyrrolidin-2-ones, as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1. T. Aicher; M. Chicarelli; C. Gauthier; R. Hinklin; H. Tian; O. Wallace; Z. Chen; T. Mabry; J. Mccowan; N. Snyder; L. Winneroski; J. Allen.
4. Heterobicyclic thiophene compounds as tyrosine kinase inhibitors and their preparation and use. J. Blake; S. Boyd; J. DeMeese; J. Gaudino; A. Marlow; J. Seo; A. Thomas; H. Tian. US 2007197537.
5. Heterobicyclic pyrazole compounds as Met tyrosine kinase inhibitors and their preparation and use. J. Blake; S. Boyd; F. Cohen; J DeMeese; K. Fong; J. Gaudino; T. Kaplan; A. Marlow; J. Seo; A. Thomas; H. Tian; W. Young.
6. Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1. T. Aicher; P. Anzeveno; A. Krasutsky; R. Li; T. Mabry; A. Saeed; N. Snyder; G. Stephenson; H. Tian; O. Wallace; L. Winneroski; Y. Xu. (Note: this patent had been applied to additional 16 countries besides of the counties designated in WO).
7. Preparation of quinoline derivatives as tyrosine kinases inhibitors. J. Gaudino; S. Boyd; A. Marlow; T. Kaplan; K. Fong; J. Seo; H. Tian; J. Blake; K. Koch.
8. Heterobicyclic Pyrazolopyridine Compounds as tyrosine kinase inhibitors and their preparation and use. J. Blake; S. Boyd; F. Cohen; J DeMeese; K. Fong; J. Gaudino; A. Marlow; J. Seo; A. Thomas; H. Tian; W. Young. Had been applied.
9. Heterobicyclic Azaindole Compounds as tyrosine kinase inhibitors and their preparation and use. J. Blake; S. Boyd; K. Fong; J. Gaudino; H. Tian. Manuscript in preparation.
